Clinical trials: Bronchogenic Cancer
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
CTC levels collected pre-surgery will be correlated with pathological samples.
- Trial name
- NCT02135679
- Testing
- Radiotherapy
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
EGFR Gene Mutation, Nonsmall Cell Lung Cancer
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
This is a study for patients with advanced non-small cell lung cancer with changes to their cancer cells called EGFR mutations. Mutated EGFR is important in the growth of cancer cells.
- Trial name
- NCT02954523
- Testing
- Dasatinib, Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Chul Kim
Non Small Cell Lung Cancer (NSCLC)
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab.
- Trial name
- CheckMate153 (NCT02066636)
- Testing
- Nivolumab
- Where
- 134 sites in United States, Canada
- Volunteers
- 1,428 people
- Sponsor
- Bristol-Myers Squibb
Resectable, Early-stage
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA)…
- Conditions
- Resectable, Early-stage, NSCLC
- Trial name
- NCT03794544
- Testing
- Durvalumab, Oleclumab, Monalizumab
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 84 people
- Sponsor
- MedImmune LLC
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer, ROS1 Proto Oncogene
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
To assess treatment effectiveness and safety of oral crizotinib administered to East Asian patients with Advanced Non-Small Cell Lung Cancer (NSCLC) that is confirmed to be positive for a ROS1 positive gene mutation…
- Conditions
- Non Small Cell Lung Cancer, ROS1 Proto Oncogene, Crizotinib
- Trial name
- NCT01945021
- Testing
- Crizotinib
- Where
- 44 sites in China, Japan and 2 more
- Volunteers
- 129 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
This Phase 3 study was a randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of tislelizumab in combination with either cisplatin or carboplatin and etoposide (Arm A), compared to…
- Trial name
- NCT04005716
- Testing
- Tislelizumab, Cisplatin, Carboplatin
- Where
- 50 sites in China
- Volunteers
- 457 people
- Sponsor
- BeiGene
Non-small Cell Lung Cancer
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor…
- Trial name
- NCT03631706
- Testing
- M7824, Pembrolizumab
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 304 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Tumors Characterized by Genetic Abnormalities of ALK
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).
- Trial name
- NCT01283516
- Testing
- LDK378
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- Novartis Pharmaceuticals
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Non-Small-Cell Lung Cancer
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
- Trial name
- NCT00482014
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 11 sites in United States, India
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28), a Cyclin Dependent Kinase (CDK) 4/6 inhibitor, in preserving the bone marrow and the immune system, in order to decrease chemotherapy-induced…
- Trial name
- NCT02514447
- Testing
- Trilaciclib, Topotecan
- Where
- 50 sites in United States, Belgium and 6 more
- Volunteers
- 123 people
- Sponsor
- G1 Therapeutics, Inc.
Non Small Cell Lung Cancer
Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)
This is a pilot study. A pilot study is done with a small number of participants to see if a technique works before using it in a larger research study.
- Trial name
- NCT01799135
- Testing
- DCE-MRI scan, Stereotactic Body Radiation Therapy, 4D-CT scan
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
- Trial name
- NCT02347917
- Testing
- BBI608, Pemetrexed, Cisplatin
- Where
- 2 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Non-small Cell Lung Cancer
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated…
- Trial name
- FOCAL (NCT02318368)
- Testing
- Ficlatuzumab, Erlotinib
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Small Cell Lung Cancer, Carcinoma, Small Cell
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.
- Conditions
- Small Cell Lung Cancer, Carcinoma, Small Cell, SCLC
- Trial name
- NCT00447421
- Testing
- pemetrexed, cisplatin, radiation
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer, Postmenopausal Women
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
- Trial name
- NCT00932152
- Testing
- fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh